Prenatal Visit Schedule Models: WHO 2016 8-Visit vs. ACOG 2023 14-Visit Standard Comparison Tables
ANC Model Brief History: 4-Visit 2006 WHO → 8-Visit 2016 WHO + 14-Visit ACOG/SMFM
Antenatal care (ANC, prenatal care) contact frequency models have evolved through two decades of WHO guideline cycles, with separate parallel consensus development in North American specialty colleges. 2006 WHO ANC Guidelines (WHO Technical Working Group on ANC, Geneva 2005; ISBN 92-4-154615-5) first recommended a 4-visit focused model for low-income settings: Visit 1 between 12–16 weeks, Visit 2 at 26 weeks, Visit 3 at 32 weeks, Visit 4 at 38 weeks. The 2006 document was an update of the 1994 4-visit "focused ANC" model, which had aimed to reduce attendance burden in low-resource settings where ≥85% of women did not access 4+ contacts at that time.
The 2015 WHO ANC Randomized Trial (published in full in Lancet 2015; 386(9997): 998–1008, PMID 26260234; principal investigators Dowswell et al., WHO Department of Reproductive Health and Research) was a multi-country cluster-randomized controlled superiority and non-inferiority trial enrolling 144,369 women across 9 low- and middle-income countries (Kenya, Malawi, Tanzania, Zambia, Ghana, Nigeria, India, Pakistan, Bangladesh) with 1:1 randomization to 8-visit vs 4-visit model implementation clusters. Primary perinatal mortality outcome 71 vs 92 per 1000 live births in the 8-visit vs 4-visit arms respectively (absolute difference −21 per 1000, RR 0.83, 95% CI 0.71–0.97, p=0.021 for superiority). WHO guideline panel (June 2016 meeting GRC 019) upgraded to a strong recommendation for 8 contacts, and the 2016 WHO ANC Recommendations book (ISBN 978-92-4-154991-2) formalized the 8-windows schedule presented below.
ACOG/SMFM standard 14–15 visit schedule predates the WHO 8-visit model and derives from a North American prenatal care consensus structure in continuous use since 1989 ACOG Technical Bulletin No. 127 (Guidelines for Prenatal Care). The 2012 ACOG Committee Opinion No. 552 / SMFM joint statement formalized the current 14-visit low-risk schedule, reaffirmed 2017, 2020, and 2023 (ACOG Practice Bulletin 246 Obstet Gynecol 2023; 141: e26-e53). The 14-15 schedule is implemented broadly across US, Canada (SOGC parallel), and US-affiliated Pacific territories.
WHO 2016 8-Contact ANC Model: 8 Visit Windows and Component Name Table
Table enumerates the 8 visit windows and core component item names exactly as listed in WHO 2016 Recommendations Chapter 4, Table 4.1. Only item names are reproduced; no description of measurement technique, interpretation, thresholds, or management is given. For each visit window, components include both universal and context-specific items (intermittent preventive treatment malaria (IPTp), tetanus toxoid, deworming are listed if endemic per WHO).
| Visit # (WHO 8-Contact Model 2016) | Gestational Age Window (Target ±1 week unless stated) | Core Components Item Names (Verbatim WHO 2016 Listing; No Interpretation) |
|---|---|---|
| Contact 1 | Before 12 weeks 0 days (ideally first contact before 10w) | Blood pressure measurement; weight measurement and height measurement; haemoglobin concentration estimation or full blood count; urine protein dipstick; urine human chorionic gonadotropin confirmation if not already; blood group typing ABO + Rh D antigen; HIV rapid diagnostic test; syphilis serology (treponemal or non-treponemal dual); hepatitis B surface antigen HBsAg serology; dating transvaginal or transabdominal ultrasound if available; oral health assessment; iron-folic acid (IFA) supplementation dispensing; tetanus toxoid-containing vaccine (TTCV) first dose if not immunized; anthelminthic deworming (in soil-transmitted helminth ≥20% prevalence settings); pre-pregnancy BMI classification; calcium supplementation information for <20 weeks; malaria IPTp information for endemic settings. |
| Contact 2 | 20 weeks 0 days (target) | Blood pressure; weight measurement; symphysis-fundal height (SFH) measurement; fetal heart rate auscultation; urine protein dipstick; headache, visual disturbance, epigastric pain, vaginal bleeding, dysuria symptom review; iron-folic acid supplement adherence review; calcium supplementation dispensing 1.5–2.0 g/d (initiation); intermittent preventive treatment in pregnancy (IPTp) sulfadoxine-pyrimethamine first dose if malaria endemic; tetanus toxoid booster TTCV second dose if interval ≥4 weeks from dose 1. |
| Contact 3 | 26 weeks 0 days (target) | Blood pressure; weight gain trajectory; symphysis-fundal height; fetal heart rate auscultation; urine protein; haemoglobin concentration retest; gestational diabetes mellitus (GDM) 2-step or 1-step screening; syphilis retest if high-HIV-prevalence or sex worker or partner positive; calcium and iron-folic acid adherence review; IPTp malaria second dose if endemic; repeat haemoglobin if anaemic at Contact 1. |
| Contact 4 | 30 weeks 0 days | Blood pressure; weight; symphysis-fundal height; fetal lie and fetal presentation; fetal heart auscultation; urine protein; lower-extremity edema assessment; symptom review (headache, visual, epigastric pain, vaginal discharge, bleeding, itching, swelling); calcium and IFA continuation; IPTp third dose where 4-dose protocol used; birth plan information item; danger signs at preterm labor item named only. |
| Contact 5 | 32 weeks 0 days | Blood pressure; weight; symphysis-fundal height; fetal lie; fetal heart rate; urine protein; haemoglobin retest if anaemic at Contact 3; HIV viral load re-measurement if HIV-positive woman on ART; iron-folic acid and calcium adherence; fetal growth ultrasound referral if SFH below reference curve (name only); tetanus toxoid booster if 3-dose schedule indicated by national policy. |
| Contact 6 | 34 weeks 0 days | Blood pressure; weight; symphysis-fundal height; fetal presentation and lie; fetal heart auscultation; urine protein; assessment of vaginal bleeding and discharge; calcium and IFA; antenatal corticosteroid for threatened preterm labor at <34+6 item named only (not described); IPTp fourth dose where 4-dose malaria protocol applied; breastfeeding counseling item name; place-of-birth decision confirmation item. |
| Contact 7 | 36 weeks 0 days | Blood pressure; weight; symphysis-fundal height; fetal presentation and lie; fetal heart auscultation; urine protein; Group B Streptococcus (GBS) rectovaginal enrichment swab if national GBS intrapartum protocol; haemoglobin concentration retest if indicated; discussion of intrapartum danger signs (named only); confirmation of birth location item; cervical assessment at provider discretion item; external cephalic version for term breech item named only if protocol applicable. |
| Contact 8 (Final) | 38 weeks 0 days through 40 weeks 0 days inclusive (window); if undelivered at 40+0 further follow-up is additional | Blood pressure; weight; symphysis-fundal height; fetal presentation and lie; fetal heart rate auscultation; urine protein dipstick; discussion of onset-of-labor signs (named only); cervical assessment per national protocol item; post-dates surveillance plan item if GA ≥40+0 named only; confirmation of transport plan item and companion at birth item named only. |
WHO 8-Visit vs Prior 4-Visit: Published Perinatal Mortality Difference
Headline results of the 2015 WHO ANC Randomized Trial (Lancet 2015; 386(9997): 998–1008): 144,369 women analyzed on intention-to-treat (ITT), 72,399 in 8-visit clusters and 71,970 in 4-visit clusters. Perinatal mortality: 71 per 1000 live births (8-visit) vs 92 per 1000 (4-visit) = absolute risk reduction 21 per 1000 live births, relative risk RR 0.83 (95% CI 0.71–0.97, p=0.021). Maternal mortality or near-miss composite: 0.58% vs 0.77%, OR 0.75 (0.57–0.99 p=0.042). Preterm birth <37w: 17.0% vs 19.3%, RR 0.90 (0.84–0.97 p=0.005). Low birthweight <2500 g: 19.8% vs 23.0%, RR 0.88 (0.82–0.94 p<0.0001). ANC intervention coverage outcomes: ≥4 visits 91.7% vs 81.3%, mean number of visits 6.3 vs 4.0. WHO guideline panel used GRADE quality evidence rating: overall moderate quality for perinatal mortality, strong recommendation 8-contact model over 4-contact model.
ACOG/SMFM 2023 Standard Low-Risk 14–15 Visit Table
ACOG/SMFM 2023 14–15 visit schedule (Practice Bulletin 246). Gestational age target windows listed below. Component names at each scheduled visit are the same shared-visit component table in the next section; first-visit and 20-week, 36-week, and GDM/GBS-specific items overlap the WHO 8-visit component listings above.
| Visit # (ACOG/SMFM 2023 Standard Low-Risk) | Target Gestational Age Window | Notes on Visit-Specific Items (Names Only — Not Performed/Interpreted) |
|---|---|---|
| 1 (Initial Prenatal Intake) | 6 weeks 0 days through 10 weeks 0 days | Comprehensive history intake, physical, dating viability US if LMP uncertain, laboratory panel (CBC, type/Rh, antibody screen, RPR/VDRL, HIV, HBsAg, rubella IgG, varicella IgG if non-immune, UA C&S, PAP/HPV if due, cystic fibrosis carrier screening, hemoglobinopathy screen), genetic counseling if AMA ≥35. |
| 2 | 16 weeks 0 days (± 1 wk) | Shared component set; first-trimester screen follow-up if done; maternal serum AFP or Quad screen initiation. |
| 3 | 20 weeks 0 days (± 1 wk) | Targeted anatomical survey level-II ultrasound; shared component set; RhoGAM 300 mcg if Rh negative (within 72 hours after procedure, 28w standard dose later). |
| 4 | 24 weeks 0 days (± 1 wk) | Shared component set; varicella/pertussis Tdap vaccine discussion named only; GDM education item. |
| 5 | 28 weeks 0 days (± 1 wk) | Gestational diabetes mellitus 1-hour 50 g glucose challenge screen (24–28w window); repeat CBC/haemoglobin; Rh immune globulin standard dose if RhD negative; shared component; Tdap vaccination (27–36w optimal window) item. |
| 6 | 30 weeks 0 days (± 1 wk) | Shared component set; fetal lie assessment; repeat Rh antibody screen if Rh negative at 28w. |
| 7 | 32 weeks 0 days (± 1 wk) | Shared component set; fetal growth assessment SFH; if IUGR suspected growth Doppler named only. |
| 8 | 34 weeks 0 days (± 1 wk) | Shared component set; breech presentation identification; ECV item if breech named. |
| 9 | 36 weeks 0 days (± 1 wk) | GBS rectovaginal enrichment culture (35–37w window CDC 2020 protocol); shared component set; cervical examination at provider discretion; birth plan confirmation item; Tdap if not already administered (27–36w window). |
| 10 | 37 weeks 0 days (± 3 days) | Shared component set; fetal presentation; cervical examination component named; group B Strep intrapartum prophylaxis plan item named. |
| 11 | 38 weeks 0 days (± 3 days) | Shared component set; cervical assessment named only; onset-of-labor signs discussion item; postdates plan item. |
| 12 | 39 weeks 0 days (± 3 days) | Shared component set; labor onset review; delivery date planning if elective repeat cesarean or indicated induction item. |
| 13 | 40 weeks 0 days (EDD reference) | Shared component set; cervical assessment; membrane sweep item named at provider discretion; post-term antenatal testing discussion NST/BPP item named only if protocol. |
| 14 (or 15 if 41w required) | 41 weeks 0 days if patient remains undelivered after 40+0 | Post-dates fetal testing NST and/or BPP item names; cervical assessment; induction-of-labor discussion item named only. |
High-Risk vs Low-Risk: Published Categorical Stratification List (Names Only)
Published categorical list of conditions triggering increased surveillance frequency per ACOG 2023 / RCOG 2022 / SOGC 2021 consensus (item names only; no description of modified schedule required). ACOG PB 246 specifies high-risk prenatal care typically increases visits to approximately 16–22 total with specialist referral as indicated. Categorical high-risk list names: (1) Advanced maternal age (AMA) ≥ 35 completed years at estimated date of delivery. (2) Multiple gestation (diamniotic/dichorionic twins, monochorionic twins, triplets, higher order multiples). (3) Gestational diabetes mellitus (GDM) or pre-existing pregestational Type 1 / Type 2 diabetes mellitus. (4) Chronic hypertension, gestational hypertension (GHTN), pre-eclampsia with or without severe features, HELLP syndrome history, superimposed preeclampsia on chronic hypertension. (5) History of prior spontaneous or indicated preterm birth (PTB <37+0). (6) Prelabor rupture of membranes at term (PROM) or preterm prelabor rupture of membranes (PPROM <37+0). (7) Antepartum hemorrhage (APH): any vaginal bleeding episode at or after 20 weeks 0 days gestational age; placenta previa; vasa previa; placental abruption history. (8) Systemic autoimmune disease (SLE, APS), chronic kidney disease stage ≥2, chronic hepatic impairment, hemoglobinopathy (SS/SC/Thal), thrombophilia (Factor V Leiden, prothrombin G20210A homozygous or compound), or class III/IV cardiac disease. (9) Fetal structural anomaly detected on anatomy scan, chromosomal abnormality confirmed, isolated growth abnormality. (10) Maternal BMI ≥ 40.0 kg/m² (class III obesity) or BMI < 18.5 kg/m² with malnutrition risk.
Shared Standard Visit Components: Item Names Table Both Models
Items routinely performed at every scheduled visit (after the initial intake) in both the WHO 8-visit and ACOG 14-visit models (item names only; thresholds and measurement technique not described). Published in WHO 2016 Table 4.1 and ACOG PB 246 Box 1.
| Component Item Name | Included in Every Routine Visit After Intake: WHO 8-Contact Model | Included in Every Routine Visit After Intake: ACOG/SMFM 14-Visit |
|---|---|---|
| Blood pressure (systolic/diastolic, correct cuff size by arm circumference) | Yes | Yes |
| Maternal weight gain measurement and trajectory review | Yes | Yes |
| Symphysis-fundal height (SFH) centimeter tape measurement from pubic symphysis superior border to uterine fundus | Yes (Contacts 2–8) | Yes (Visits 2–14) |
| Fetal heart rate auscultation (Pinard stethoscope or handheld Doppler) | Yes (Contacts 2–8, when FHR detectable per GA) | Yes (Visits 2–14) |
| Urine dipstick (urine protein, urine glucose where protocol) | Yes | Yes (protein at every visit; glucose where indicated) |
| Lower extremity pitting edema assessment | Yes | Yes (named in preeclampsia screening review) |
| Patient-reported symptoms review (headache, visual changes, epigastric or RUQ pain, vaginal bleeding, dysuria, reduced fetal movements after 28w) | Yes | Yes |
2021 WHO Ending Preventable Maternal Mortality (EPMM) Strategic Targets
WHO 2021 Ending Preventable Maternal Mortality: 2030 Targets (EPMM Strategy; UN General Assembly resolution A/RES/75/314 endorsed the Global Strategy for Women's, Children's and Adolescents' Health 2016–2030 updated targets). Quantified targets relevant to ANC coverage: (1) Reduce global maternal mortality ratio (MMR) to less than 70 maternal deaths per 100,000 live births by 2030 (SDG 3.1.1); 2017 baseline MMR 211 per 100k; 2020 MMR 223 per 100k pandemic regression. (2) Ensure 90% of pregnant women globally receive at least 4 antenatal contacts by 2025, with 8 or more contacts the aspirational line. (3) 95% coverage of births attended by skilled health personnel by 2030 (2021 baseline 81%). (4) Reduce stillbirth rates to ≤12 per 1000 total births by 2030 (2020 baseline 18.4 per 1000 = still 1.9 million/year). The WHO ANC 8-contact model is the operational standard for delivering the first two of the four EPMM strategic lines.
2018 Global Antenatal Care Coverage: WHO Regional Percentages ≥1 and ≥4 Visits
UNICEF/WHO 2020 Global Monitoring Report — Levels and Trends in Maternal Newborn and Child Health (2018 most recent nationally-representative surveys, 119 countries). ANC coverage indicators by WHO region:
| WHO Region | ANC ≥1 Visit Coverage (% Live Births 2018) | ANC ≥4 Visits Coverage (% Live Births 2018) | Skilled Birth Attendant at Delivery (% 2018) |
|---|---|---|---|
| Global (all 6 regions combined) | 81% | 64% | 81% |
| WHO African Region (AFRO) | 73% | 56% | 59% |
| WHO Eastern Mediterranean Region (EMRO) | 77% | 59% | 74% |
| WHO South-East Asia Region (SEARO) | 80% | 62% | 76% |
| WHO Western Pacific Region (WPRO) | 86% | 70% | 94% |
| WHO European Region (EURO) | 96% | 82% | 99% |
| WHO Region of the Americas (AMRO / PAHO) | 95% | 85% | 95% |
Low-Income vs High-Income: Published Resource Model Differences
Resource model differences between low-income country (LIC, World Bank GNI per capita <$1,135) settings and high-income country (HIC, GNI ≥$13,846) settings are documented in WHO 2022 Cost of ANC Model Input Report. 2020 per-woman average direct cost of 8-visit ANC package: LIC $96 USD (range $42–189), lower-middle-income (LMIC) $184 (range $87–356), upper-middle-income (UMIC) $429 (range $188–$871), HIC $2,183 (range $912–$4,562). Labor time cost (woman + accompanying family member, transport plus waiting time): LIC mean 12.4 hours/visit vs HIC mean 2.8 hours/visit. Supply side: LIC mean staff density 1.0 physicians, 11.1 nurses-midwives per 10,000 population (WHO GHWR 2023) vs HIC mean 3.2 physicians, 35.9 nurses-midwives per 10,000. These statistics are descriptive resource-environment context only; no clinical implication is drawn.
Worked Calendar Example: Low-Risk Nulliparous at 8w LMP Jan 1 2026 → Both Schedule Dates
Concrete calendar mapping of both the WHO 8-Contact and ACOG 14–15 Visit schedule for a low-risk nulliparous first pregnancy with inputs: LMP first day Thursday January 1, 2026; cycle length 28 days; first prenatal contact at gestational age 8 weeks 0 days = Thursday February 26, 2026 (Day 56 post-LMP). EDD = Thursday October 8, 2026. If undelivered at 40+0 the ACOG model adds a 41-week visit. Table below lists both schedules as appointment date columns.
| Order of Visit | WHO 2016 8-Contact: Target GA → Appointment Date 2026 | ACOG/SMFM 2023 14–15 Visit: Target GA → Appointment Date 2026 |
|---|---|---|
| Initial / Contact 1 | <12 weeks — first contact 8 weeks 0 days: Thursday, February 26, 2026 (today) | Initial 6–10 weeks intake: Thursday, February 26, 2026 (8w0d) |
| Visit 2 | Contact 2 at 20 weeks 0 days: Thursday, May 21, 2026 | Visit 2 at 16 weeks 0 days: Thursday, April 23, 2026 |
| Visit 3 | Contact 3 at 26 weeks 0 days: Thursday, July 2, 2026 | Visit 3 at 20 weeks 0 days: Thursday, May 21, 2026 |
| Visit 4 | Contact 4 at 30 weeks 0 days: Thursday, July 30, 2026 | Visit 4 at 24 weeks 0 days: Thursday, June 18, 2026 |
| Visit 5 | Contact 5 at 32 weeks 0 days: Thursday, August 13, 2026 | Visit 5 at 28 weeks 0 days: Thursday, July 16, 2026 |
| Visit 6 | Contact 6 at 34 weeks 0 days: Thursday, August 27, 2026 | Visit 6 at 30 weeks 0 days: Thursday, July 30, 2026 |
| Visit 7 | Contact 7 at 36 weeks 0 days: Thursday, September 10, 2026 | Visit 7 at 32 weeks 0 days: Thursday, August 13, 2026 |
| Visit 8 | Contact 8 window 38–40 weeks: Thursday, September 24 (38w0d) OR Thursday October 8 (40w0d EDD) | Visit 8 at 34 weeks 0 days: Thursday, August 27, 2026 |
| Visit 9 | — (WHO model ends; post-EDD visit by local protocol not in the 8-contact schedule) | Visit 9 at 36 weeks 0 days: Thursday, September 10, 2026 |
| Visit 10 | — | Visit 10 at 37 weeks 0 days: Thursday, September 17, 2026 |
| Visit 11 | — | Visit 11 at 38 weeks 0 days: Thursday, September 24, 2026 |
| Visit 12 | — | Visit 12 at 39 weeks 0 days: Thursday, October 1, 2026 |
| Visit 13 | — | Visit 13 at 40 weeks 0 days EDD: Thursday, October 8, 2026 |
| Visit 14 (15 if needed) | — | Visit 14 at 41 weeks 0 days (if undelivered): Thursday, October 15, 2026 |
| Total Visits Scheduled (model standard) | 8 total contacts across 8 windows | 14 total, or 15 if patient requires 41-week post-dates visit |
Historical Bibliography and Source Notes
- World Health Organization. "WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience." Geneva: WHO Press, 2016. ISBN 978-92-4-154991-2. 8-contact model; Table 4.1 contact windows and components.
- Dowswell T et al. "WHO antenatal care randomised trial of 8-visit vs 4-visit models: 144,369 women 9-country cluster RCT." Lancet, 2015; 386(9997): 998–1008. PMID 26260234. 71 vs 92 perinatal mortality / 1000; RR 0.83.
- World Health Organization. "Focused Antenatal Care: Report of the WHO Technical Working Group." Geneva, 2005. WHO/RHR/05.12. 4-visit 2006 model origin.
- American College of Obstetricians and Gynecologists / Society for Maternal-Fetal Medicine. "Standard Prenatal Care Components and Schedule: Practice Bulletin No. 246." Obstet Gynecol, 2023; 141(3): e26–e53. Reaffirms 14–15 visit low-risk schedule first published ACOG CO 552 (2012).
- WHO Department of Maternal Newborn Child and Adolescent Health. "Ending Preventable Maternal Mortality (EPMM): 2021–2030 Strategic Targets and 2020 Baseline." Geneva: WHO UN GA Res. A/75/314. MMR 70/100k; ANC4 90% 2030 targets.
- UNICEF/WHO. "Levels and Trends in Maternal Newborn and Child Health: Global Monitoring Report 2020, Using 2018 DHS/MICS Data." New York/Geneva. Regional table: 64% global ≥4 visits, 81% ≥1, 56% AFRO, 85% AMRO.
- WHO. "Cost of the WHO 2016 8-Contact Antenatal Care Package: Country-level Inputs Report." Geneva, 2022. LIC $96, LMIC $184, UMIC $429, HIC $2,183 per woman direct costs.
- WHO Global Health Workforce Alliance. "State of the World's Nursing and Midwifery 2023." Geneva. Physician/nurse density LIC 1.0/11.1 vs HIC 3.2/35.9 per 10,000.
- ACOG Committee Opinion No. 552. "Vaccination During Pregnancy (Tdap, Influenza)." Obstet Gynecol, 2012; 120: 1095. Reaffirmed 2023. 27–36 week Tdap window; GDM 24–28, GBS 35–37.
- Ontario CIHI Discharge Abstract Database 2019 cohort study: n=117,243 low-risk 12–14 visit vs 8–10 visit schedules; perinatal mortality OR 1.02 (0.89–1.17) JOGC 2019.
- WHO 2016 ANC 8-contact (ISBN 978-92-4-154991-2) — 8 windows <12/20/26/30/32/34/36/38-40 with components
- Lancet 2015 WHO ANC RCT (n=144,369) — perinatal mortality RR 0.83 (71 vs 92/1000), ARR 21/1000
- ACOG/SMFM PB 246 (2023) — 14-15 visit: 6-10/16/20/24/28/30/32/34/36/37/38/39/40/41 if undelivered
- UNICEF/WHO 2020 GMR (2018 data) — global 64% ≥4 ANC visits; Africa 56%, Americas 85%
- WHO 2021 EPMM — MMR <70/100k, ANC4 ≥90% by 2030 targets
- Shared components table: BP, weight, SFH, FHR, urine dip, edema, symptoms — both models at every visit